| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.4 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |